Acute reversible neurological deficit following intrathecal chemotherapy.
We report on two patients with non-Hodgkin's lymphoma (NHL) who developed reversible, short-lived neurological deficit following intrathecal (i.t.) chemotherapy. One patient received i.t. methotrexate for treatment of meningeal disease, and the other received i.t. methotrexate with cytosine arabinoside (ara-C) and hydrocortisone as central nervous system (CNS) prophylaxis. Although transient paresis following i.t. chemotherapy has previously been reported, it has been attributed to the preservatives contained in the diluents. Our two patients, however, received preservative-free solutions.
Dunkelman
H
H
Department of Radiotherapy and Oncology, University College Hospital, London, UK.
Earl
H M
HM
Twelves
C
C
D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007278:Injections, Spinal / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D010243:Paralysis / Q000139:chemically induced*; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects
D011310:Preservatives, Pharmaceutical; D003561:Cytarabine; D008727:Methotrexate